NASDAQ : TNGX
Tango Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 21.91 USD (Oct 30, 2026, 3:18 PM EDT) · Market cap 3.69B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 3.83B |
| Enterprise Value | 2.85B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 168.61M |
| Shares Outstanding | 168.61M |
| Shares Change (YoY) | +22.81% |
| Shares Change (QoQ) | +4.39% |
| Owned by Insiders (%) | 1.07% |
| Owned by Institutions (%) | 100.94% |
| Float | 120.67M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 71.19 |
| Forward PS | 1,697.20 |
| PB Ratio | 3.73 |
| P/TBV Ratio | 3.74 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 52.94 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 50.82 |
| Quick Ratio | 49.95 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -21.34% |
| Return on Assets (ROA) | -12.99% |
| Return on Invested Capital (ROIC) | -13.90% |
| Return on Capital Employed (ROCE) | -12.94% |
| Weighted Average Cost of Capital (WACC) | 10.60% |
| Revenue Per Employee | $392,781 |
| Profits Per Employee | -$903,073 |
| Employee Count | 137 |
| Asset Turnover | 0.08 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | -63,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.17 |
| 52-Week Price Change | +190.17% |
| 50-Day Moving Average | 23.61 |
| 200-Day Moving Average | 22.33 |
| Relative Strength Index (RSI) | 46.69 |
| Average Volume (20 Days) | 4,647,716 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 44.78M |
| Short Previous Month | 44.50M |
| Short % of Shares Out | 26.56% |
| Short % of Float | 37.11% |
| Short Ratio (days to cover) | 11.90 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 53.81M |
| Gross Profit | -79.84M |
| Operating Income | -136.35M |
| Pretax Income | -123.78M |
| Net Income | -123.72M |
| EBITDA | -134.43M |
| EBIT | -136.35M |
| Loss Per Share | -$0.91 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 1.01B |
| Total Debt | 31.99M |
| Net Cash | 982.00M |
| Net Cash Per Share | $5.82 |
| Equity (Book Value) | 1.02B |
| Book Value Per Share | 6.08 |
| Working Capital | 1.01B |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -143.90M |
| Capital Expenditures | -373,000 |
| Depreciation & Amortization | 1.92M |
| Net Borrowing | n/a |
| Free Cash Flow | -144.27M |
| FCF Per Share | -$0.86 |
Margins
| Measure | Value |
|---|
| Gross Margin | -148.37% |
| Operating Margin | -253.38% |
| Pretax Margin | -230.03% |
| Profit Margin | -229.92% |
| EBITDA Margin | -249.81% |
| EBIT Margin | -253.38% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -22.81% |
| Shareholder Yield | -22.81% |
| Earnings Yield | -4.03% |
| FCF Yield | -3.77% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $47.09 |
| Price Target Difference | 107.26% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 13 |
| Revenue Growth Forecast (3Y) | -16.49% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 21.98 |
| Piotroski F-Score | 3 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |